NASDAQ · Biotechnology

COYA (COYA) Stock

$4.00 -6.21% NASDAQ: COYA Healthcare

Valuation

MetricValue
Price$4.00
Market Cap$72.84M
P/E Ratio-2.62
P/B Ratio2.29
P/S Ratio10.99
EPS (TTM)$0.00
52-Week High$7.75
52-Week Low$3.71
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-51.31%
ROA-27.57%
ROCE-46.51%
Gross Margin99.79%
Operating Margin-2.77%
Net Margin-2.66%
Debt/Equity0.00
Current Ratio8.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$6.0M$4.0M$8.0M
Operating Profit$-5.0M$-10.0M$-8.0M$-17.0M$-20.0M
Net Profit$-5.0M$-12.0M$-8.0M$-15.0M$-21.0M
EPS$-0.74$-1.23$-0.79$-0.98$-1.27
Op Margin——-131.7%-485.4%-255.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$8.0M$41.0M$44.0M$50.0M
Total Liabilities$1.0M$17.0M$6.0M$5.0M$7.0M
Cash$4.0M$6.0M$33.0M$38.0M$47.0M
Borrowings$0$13.0M$0$0$0

Latest News

Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year? Zacks · Jun 30, 2026 Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting Business Wire · Jun 18, 2026 Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease Business Wire · Jun 15, 2026 Coya Therapeutics Says Phase 2 ALS Study Enters Blinded Extension Phase MT Newswires · Jun 8, 2026 Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase Business Wire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-7.0M$-11.0M$-10.0M$-11.0M
Investing Cash Flow$0$-1.0M$-1.0M$0$-1.0M
Financing Cash Flow$0$-1.0M$0$2.0M$0
Net Cash Flow$-4.0M$2.0M$27.0M$6.0M$8.0M
Free Cash Flow$-4.0M$-7.0M$-11.0M$-10.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.99
FCF Yield-16.19%
Quick Ratio15.02
Interest Coverage—
Return 1Y-20.33%
Return 3Y20.20%
Return 5Y—

Ownership

Insiders Held14.69%
Institutions Held35.37%
Institutions Float Held41.46%
Institutional HolderSharesReport Date
DME Capital Management, LP2,335,5402026-03-31
AIGH Capital Management LLC975,4042026-03-31
Vanguard Capital Management LLC844,9132026-03-31
Alyeska Investment Group, L.p.800,0002026-03-31
Prosight Management, Lp420,3602026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLNNClene Inc. $5.29 -1.86% -1.66 $54.53M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
IMMX $8.55 +4.65% -9.96 $465.14M 0.00%
MGNX $3.78 +3.00% -2.92 $240.27M 0.00%
ORMP $4.39 +7.86% 2.85 $179.67M 5.84%

About COYA

COYA is led by CEO Arun Swaminathan, employs 8 people, headquartered in US, publicly traded since 2022.

COYA stock trades at $4.00 with a market capitalization of $72.84M. The stock is valued at a price-to-earnings (P/E) ratio of -2.62, price-to-book of 2.29, price-to-sales of 10.99. Over the past 52 weeks the stock has ranged between $3.71 and $7.75, and currently trades 48.4% below its 52-week high.

On profitability, COYA generates a return on equity (ROE) of -51.31%, return on capital employed of -46.51%, an operating margin of -2.77%, a net profit margin of -2.66%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides